Table 1:
Demographic, clinical, and white matter hyperintensity characteristics between patients with Parkinson disease with and without mild cognitive impairment
| Demographic and Clinical Variables | PD-NCI (n = 65) | PD-MCI (n = 25) | P Value |
|---|---|---|---|
| Age (yr) (mean) (SD) | 63.4 (7.6) | 69.4 (6.4) | .001a,b |
| Sex (male) (No.) (%) | 46 (72.3) | 18 (76.0) | .723c |
| Education (yr) (mean) (SD) | 11.0 (3.1) | 9.3 (3.5) | .032a,d |
| Hoehn and Yahr (mean) (SD) | 1.9 (0.4) | 1.8 (0.4) | .357d |
| Disease duration (yr) (mean) (SD) | 5.4 (4.3) | 5.0 (2.7) | .910d |
| UPDRS (mean) (SD) | 17.5 (7.0) | 20.0 (8.4) | .167b |
| Levodopa equivalent dose (mg) (mean) (SD) | 557.4 (375.7) | 510.2 (299.0) | .767d |
| Cardiovascular risk factors (No.) (%) | |||
| Diabetes | 5 (7.8) | 8 (32.0) | .004a,c |
| Hypertension | 20 (31.3) | 13 (52.0) | .069c |
| Hyperlipidemia | 20 (31.3) | 14 (56.0) | .031a,c |
| Smoking | 15 (23.4) | 6 (24.0) | .955c |
| White matter hyperintensities | |||
| Total WMH volume (mm) (mean) (SD) | 4.2 (5.8) | 12.3 (10.3) | <.001a,e |
Note:—UPDRS indicates Unified Parkinson's Disease Rating Scale, subscore III; WMH, white matter hyperintensities.
a
Significant differences at P < .05 level.
b
Student t test.
c
χ2 test.
d
Mann-Whitney U test.
e
Analysis of covariance test, corrected for age, sex, and education.